NCT07946913
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change from baseline in weekly Urticaria Activity Score (UAS7) at week 12
Timeframe: Week 12
Secondary (8)
Change from baseline in UAS7 at each assessment visit (excluding Week 12)
The proportion of participants with UAS7 = 0 at each assessment visit
The proportion of participants with UAS7 ≤ 6at each assessment visit
Change From Baseline in weekly hives severity score (HSS7) at each assessment visit.
Change From Baseline in weekly itch severity score ( ISS7) at each assessment visit.
Show 3 moreShow less
Change From Baseline in weekly angloedema activity score (AAS7) at each assessment visit.
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at each assessment visit
The incidence of adverse events during the study
Arms and interventions
LP-003 groupExperimental
Participants received LP-003 subcutaneously during the 48-week treatment period
Omalizumab groupActive comparator
Participants received omalizumab subcutaneously during the 48-week treatment period
Biologicals: LP-003 Injection, Omalizumab
Sites
2 sites in 1 country